PRESS RELEASE : Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

DGAP-News: Immunic, Inc. / Key word(s): Conference 
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April 
2021-04-13 / 12:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April 
NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a 
pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today 
announced participation in the following scientific, investor and industry conferences in April: 
- April 17-22: 2021 Virtual American Academy of Neurology (AAN) Annual Meeting. Robert J. Fox, M.D., Staff Neurologist, 
Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, 
will present the full data set from Immunic's phase 2 EMPhASIS trial of its lead asset, IMU-838, in patients with 
relapsing-remitting multiple sclerosis at the 2021 Virtual AAN Annual Meeting. 
- Abstract Number: 2872 
- Title: Efficacy and Safety of the Selective Oral DHODH Modulator Vidofludimus Calcium (IMU-838) in 
Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Phase 2 Trial (EMPhASIS) 
- Session Title: P15: MS Clinical Trials and Therapeutics 
- Program Number: P15.085 
The poster presentation, including an audio track, will be available in the virtual poster hall the entire length of 
the meeting and for thirty days after the conference. The poster will also be accessible on the "Events and 
Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. In addition, Dr. Fox will be 
available for a virtual one-on-one discussion to address any questions regarding the poster on Monday, April 19, from 
12:30 to 1:00 pm ET via the conference portal. 
- April 28-29: Virtual B. Riley Neuroscience Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of 
Immunic, will participate in a fireside chat on Wednesday, April 28, at 9:30 am ET. Specific details regarding webcast 
and replay information will be published on the "Events and Presentations" section of Immunic's website at: ir.imux.com 
/events-and-presentations, once they are available. 
- April 28-30: German Corona Showcase 2021 (held in English). Dr. Vitt will present an overview of Immunic's phase 2 
CALVID-1 trial of IMU-838 in moderate COVID-19 on Friday, April 30, at 10:50 am CET (4:50 am ET). Specific details 
regarding webcast and replay information will be published on the "Events and Presentations" section of Immunic's 
website at: ir.imux.com/events-and-presentations, once they are available. 
About Immunic, Inc. 
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology 
therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small 
molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular 
metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is 
currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, COVID-19, 
and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?t, is targeted 
for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal 
barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, 
please visit: www.imux.com. 
Cautionary Statement Regarding Forward-Looking Statements 
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes 
of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than 
statements of historical facts, included in this press release regarding strategy, future operations, future financial 
position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking 
statements. Examples of such statements include, but are not limited to, statements relating to management's 
participation in scientific, investor and industry conferences. Immunic may not actually achieve the plans, carry out 
the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not 
place undue reliance on these forward-looking statements. Such statements are based on management's current 
expectations and involve risks and uncertainties. Actual results and performance could differ materially from those 
projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 
pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed 
for contingent future liabilities and business operations, the availability of sufficient resources to meet business 
objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive 
of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, 
risks related to the drug development and the regulatory approval process and the impact of competitive products and 
technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in 
the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 
31, 2020, filed with the SEC on February 26, 2021, and in the company's subsequent filings with the Securities and 
Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any 
forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent 
or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date 
on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on 
any or all the contents of this press release. 
Contact Information 
Immunic, Inc. 
Jessica Breu 
Head of Investor Relations and Communications 
[phone] 
[e-mail] 
US IR Contact 
Rx Communications Group 
Paula Schwartz 
[phone] 
[e-mail] 
US Media Contact 
KOGS Communication 
Edna Kaplan 
[phone] 
[e-mail] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-04-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1183612 2021-04-13

(END) Dow Jones Newswires

April 13, 2021 06:30 ET (10:30 GMT)